Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about the maintenance and discontinuation question, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
One third of STEP 4 participants held most of their loss without the drug, and nobody has convincingly characterised who they are. That subgroup is the most interesting unanswered question in the field and it is routinely flattened into the two-thirds headline.
The condition it depends on
The caveat that "maintenance dose" in the literature almost always means the top studied dose. Lower maintenance doses are widely used and thinly evidenced, which is worth knowing before you cite anything as established.
What I am not sure about
What I am after is whether there is a lowest maintenance dose with actual maintenance data behind it, or whether everything published sits at the top of the ladder. Not looking for reassurance. Looking for the part I have got wrong.
MikeFit_NJ said:One third of STEP 4 participants held most of their loss without the drug, and nobody has convincingly characterised who they are.
MikeFit_NJ has the substance of this right. The condition it depends on is worth stating. Extending the interval and reducing the dose are pharmacologically different. Reducing the dose lowers the whole exposure curve evenly; extending the interval keeps the peak and drops the trough. Since the appetite effect tracks the trough, interval extension tends to give you good days and bad days rather than a uniformly smaller effect, which most people find harder to live with.
I would rather be corrected than agreed with, if it comes to it.
MikeFit_NJ said:One third of STEP 4 participants held most of their loss without the drug, and nobody has convincingly characterised who they are.
The regain framing needs pushing back on. Two thirds regained means one third did not, and the trial provided no ongoing support to either group. Treating regain as pharmacologically inevitable is as unsupported as treating maintenance as automatic.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThis one has a reasonably settled answer, so here it is. STEP 4 is the study that answers this and it is blunt. Participants who continued kept losing; participants switched to placebo regained about two thirds of what they had lost within a year, and the metabolic improvements faded with the weight. That is the same pattern as every other chronic-disease medication ever withdrawn, and it is an argument about the condition rather than about the drug.
NeuroNate said:Extending the interval and reducing the dose are pharmacologically different.
Right, and protein targets should be set on a reference weight rather than current weight. Setting 1.6 g/kg on a starting weight of 130kg produces a target nobody hits on a suppressed appetite.